[EN] PYRIDAZIN-3 (2H) -ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS<br/>[FR] DERIVES DE PYRIDAZINE-3(2H)-ONES ET UTILISATION EN TANT QU'INHIBITEURS DE PDE4
申请人:ALMIRALL PRODESFARMA SA
公开号:WO2005049581A1
公开(公告)日:2005-06-02
New pyridazin-e-(2H)-one derivatives having the chemical structure of general formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of phosphodiesterase 4.
Isoxazolo [3,4-d]pyridazin-7(6h)-ones. synthesis of 3-unsubstituted derivatives: A reinvestigation
作者:V. Dal Piaz、G. Ciciani、M.P. Giovannoni
DOI:10.1016/s0040-4039(00)79730-9
日期:1991.7
The structure of the major product from 1 and methylhydrazine is established and a mechanism for the formation of2 involving a preliminary nucleophilic attack at the isoxazole C-5 is proposed.
Development of methodologies for the regioselective synthesis of four series of regioisomer isoxazoles from β-enamino diketones
作者:Raí G. M. Silva、Michael J. V. da Silva、Andrey P. Jacomini、Sidnei Moura、Davi F. Back、Ernani A. Basso、Fernanda A. Rosa
DOI:10.1039/c7ra13343j
日期:——
are reported for the regioselectivesynthesis of four series of regioisomer isoxazoles from cyclocondensation of β-enamino diketones and hydroxylamine hydrochloride. Regiochemical control was achieved by varying reaction conditions and substrate structure. The mild reaction conditions used to access 4,5-disubstituted, 3,4-disubtituted, and 3,4,5-trisubstituted regioisomer isoxazoles, as well as the pharmacological
Tunable Key [3 + 2] and [2 + 1] Cycloaddition of Enaminones and α-Diazo Compounds for the Synthesis of Isomeric Isoxazoles: Metal-Controlled Selectivity
作者:Wenli Song、Yunyun Liu、Nan Yan、Jie-Ping Wan
DOI:10.1021/acs.orglett.3c00636
日期:2023.3.31
esters/ketones, and t-butyl nitrite (TBN) for the switchable synthesis of isomeric isoxazoles have been realized. The catalysis with Cu(II) salt provides 3,4-disubsituted isoxazoles via [3 + 2] cycloaddition. On the other hand, the catalysis of Ag(I) with identical substrates leads to isomeric isoxazoles with reversed C3 and C4 substitution based on a key [2 + 1] cycloaddition.
Fatty acid binding protein (FABP4) inhibitors are of synthetic and therapeutic interest and ongoing clinical studies indicate that they may be a promise for the treatment of cancer, as well as other diseases. As part of a broader research effort to develop more effective FABP4 inhibitors, we sought to identify new structures through a two-step computing assisted molecular design based on the established